{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:01:42Z","timestamp":1794837702030,"version":"4.9.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"abstract":"<jats:p>The objective of this study was to construct a concise prediction model for serious adverse events (SAEs) in order to assess the likelihood of SAE occurrence among hospitalized patients undergoing concurrent chemoradiotherapy. An electronic database of a Cancer Centre was utilized to conduct a cross-sectional review survey. Our research involved the recruitment of 239 patients who were undergoing concurrent chemoradiotherapy in the Department of Nasopharynx and Radiotherapy. The clinical prediction rule was derived using logistic regression analysis, with SAE serving as the primary outcome. Internal verification was conducted. The occurrence rate of SAE in the derivation cohort was 59.4%. The ultimate model used had 3 variables, namely cystatin C, C-reactive protein, and serum amyloid A. The model exhibited an area under the curve of 0.626 (95% CI: 0.555\u20130.696; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). The model accurately predicts the occurrence of SAE, and the variable data can be easily obtained, and the assessment technique is straightforward.<\/jats:p>","DOI":"10.1097\/md.0000000000039377","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:06:03Z","timestamp":1724648763000},"page":"e39377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma"],"prefix":"10.1097","volume":"103","author":[{"given":"Jiahui","family":"Li","sequence":"first","affiliation":[{"name":"School of Nursing, Sun Yat-sen University, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Phase I Clinical Trials, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4896-5324","authenticated-orcid":false,"given":"Huiying","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Nursing, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4143\/crt.2017.180","article-title":"Pretreatment serum amyloid A and C-reactive protein comparing with Epstein-Barr virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study.","volume":"50","author":"Chen","year":"2018","journal-title":"Cancer Res Treat"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fonc.2019.00089","article-title":"Effect of CRP and kinetics of CRP in prognosis of nasopharyngeal carcinoma.","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma.","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline.","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.intimp.2017.02.027","article-title":"The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma.","volume":"46","author":"Cong","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"307","DOI":"10.33549\/physiolres.934212","article-title":"NGAL, albumin and cystatin C during cisplatin therapy.","volume":"69","author":"Florova","year":"2020","journal-title":"Physiol Res"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"112758","DOI":"10.1016\/j.ejmech.2020.112758","article-title":"Chemotherapy and chemo-resistance in nasopharyngeal carcinoma.","volume":"207","author":"Guan","year":"2020","journal-title":"Eur J Med Chem"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.2147\/CMAR.S263100","article-title":"Predictive value of some inflammatory indexes in the survival and toxicity of nasopharyngeal carcinoma.","volume":"12","author":"Han","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2217\/bmm-2018-0401","article-title":"A novel prognostic marker based on risk stratification with prognostic nutritional index and age for nasopharyngeal carcinoma patients who received neoadjuvant chemotherapy.","volume":"13","author":"He","year":"2019","journal-title":"Biomark Med"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.canrad.2021.05.006","article-title":"Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: clinical efficacy and late toxicity.","volume":"26","author":"Hommadi","year":"2022","journal-title":"Cancer Radiother"},{"key":"R11-20250503","first-page":"505","article-title":"Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.","volume":"6","author":"Kos","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7150\/jca.17458","article-title":"Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy.","volume":"8","author":"Li","year":"2017","journal-title":"J Cancer"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40169-019-0252-7","article-title":"The prognostic value of integration of pretreatment serum amyloid A (SAA)-EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma.","volume":"9","author":"Li","year":"2020","journal-title":"Clin Transl Med"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.","volume":"145","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.7150\/jca.20351","article-title":"Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China.","volume":"8","author":"Liang","year":"2017","journal-title":"J Cancer"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm (2020)"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fonc.2020.00930","article-title":"Quality of life, toxicity and unmet needs in nasopharyngeal cancer survivors.","volume":"10","author":"McDowell","year":"2020","journal-title":"Front Oncol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2008.01.079","article-title":"Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer.","volume":"368","author":"Michaeli","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"e0193695","DOI":"10.1371\/journal.pone.0193695","article-title":"Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease.","volume":"13","author":"Ogawa-Akiyama","year":"2018","journal-title":"PLoS One"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology.","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1749-4486.2007.01543.x","article-title":"Comorbidity in nasopharyngeal carcinoma: a preliminary communication on the prevalence, descriptive distribution and impact on outcome.","volume":"32","author":"Ramakrishnan","year":"2007","journal-title":"Clin Otolaryngol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cccn.2004.02.011","article-title":"Serum cystatin C in patients with head and neck carcinoma.","volume":"344","author":"Strojan","year":"2004","journal-title":"Clin Chim Acta"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"e0143080","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review.","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer.","volume":"18","author":"Singh","year":"2019","journal-title":"Ann Afr Med"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"e1001381","DOI":"10.1371\/journal.pmed.1001381","article-title":"Prognosis Research Strategy (PROGRESS) 3: prognostic model research.","volume":"10","author":"Steyerberg","year":"2013","journal-title":"PLoS Med"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"e0167967","DOI":"10.1371\/journal.pone.0167967","article-title":"The C-reactive protein to albumin ratio as a predictor of severe side effects of adjuvant chemotherapy in stage III colorectal cancer patients.","volume":"11","author":"Tominaga","year":"2016","journal-title":"PLoS One"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40880-017-0257-9","article-title":"Nasopharyngeal carcinoma incidence and mortality in China, 2013.","volume":"36","author":"Wei","year":"2017","journal-title":"Chin J Cancer"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.oraloncology.2017.04.015","article-title":"Establishing and applying nomograms based on the 8th edition of the UICC\/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.","volume":"69","author":"Xu","year":"2017","journal-title":"Oral Oncol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.2147\/OTT.S137002","article-title":"The prognostic value of C-reactive protein\/albumin ratio in human malignancies: an updated meta-analysis.","volume":"10","author":"Xu","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12935-021-02158-6","article-title":"Development and validation of a risk prediction score for patients with nasopharyngeal carcinoma.","volume":"21","author":"Xue","year":"2021","journal-title":"Cancer Cell Int"},{"key":"R33-20250503","first-page":"237","article-title":"Serum amyloid A (SAA).","volume":"53 Su Pt 1","author":"Yamada","year":"1995","journal-title":"Nihon Rinsho"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2020.00146","article-title":"Prognostic value of clinical biochemistry-based indexes in nasopharyngeal carcinoma.","volume":"10","author":"Zeng","year":"2020","journal-title":"Front Oncol"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1111\/jcmm.15097","article-title":"Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma.","volume":"24","author":"Zeng","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015.","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"619625","DOI":"10.3389\/fonc.2020.619625","article-title":"The clinical outcomes and toxicities of induction chemotherapy followed by concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.","volume":"10","author":"Zou","year":"2020","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:05:01Z","timestamp":1746317101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":38,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039377","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}